You are here

Positive Phase III Results for Antifungal Agent Efinaconazole in Treatment of Nail Infections

Cure rates significantly higher versus vehicle at 1 year (Nov. 26)

The Journal of the American Academy of Dermatology has published the results from two pivotal, randomized, double-blind, vehicle-controlled studies that investigated the safety and efficacy of efinaconazole 10% topical solution (Valeant Pharmaceuticals) — the first triazole antifungal agent developed for distal lateral subungual onychomycosis (DLSO).

Onychomycosis is a common nail infection caused predominantly by dermatophyte fungi, resulting in nail destruction and deformity. The only approved topical treatments are lacquers with limited efficacy. Oral treatments, while more efficacious, are limited by drug interactions and numerous safety concerns, including the potential for acute liver injury.

The two phase III trials were conducted in subjects with DLSO affecting at least one great toenail. The toenail was required to have at least 20% to 50% clinical involvement. Study 1 enrolled 870 subjects, and Study 2 enrolled 785 subjects. The subjects were randomly assigned to treatment with efinaconazole topical solution 10% or vehicle. Treatment was applied once-daily for 48 weeks, with post-treatment follow-up at week 52. Debridement was not performed in either study.

The primary endpoint of both trials was the complete cure rate (defined as no clinical involvement and no evidence of fungus present by both KOH [potassium hydroxide] testing and a negative fungal culture in the target nail) at week 52. In Study 1, 17.8% of subjects treated with efinaconazole were completely cured, compared with 3.3% of subjects treated with vehicle, and in Study 2, 15.2% of subjects treated with efinaconazole were completely cured, compared with 5.5% of subjects treated with vehicle. Using the secondary endpoint of complete or almost complete cure (defined as ≤ 5% clinical involvement and 100% mycologic cure), cure rates for efinaconazole increased by 26.4% and 23.4%, respectively.

Both studies also found that mycologic cure rates were significantly (P P

Adverse events were generally mild and transient and were similar between subjects treated with efinaconazole solution 10% and vehicle.

Source: Valeant Pharmaceuticals; November 26, 2012.

Recent Headlines

Beagles Beat Out Advanced Technology
Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma
Cell Reprogramming Process May Benefit Patients Prone to Severe Hypoglycemia
Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission